Browse Articles

  • News Feature |

    Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.

    • Maureen Riordan
    •  & Amanda Micklus
  • Advertisement Feature |

    By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.

    • Kineta, Inc.
  • Advertisement Feature |

    Using its MicroRx platform, 4D pharma is pioneering the development of an emerging class of therapeutics known as live biotherapeutic products to treat a range of indications from cancer and respiratory disease to neurodegeneration.

    • 4D Pharma PLC
  • Advertisement Feature |

    Sorrento Therapeutics, Inc. is developing a pipeline of fully human immunotherapies selected from its proprietary G-MAB library. Backed by a platform covering discovery, advanced clinical development, manufacturing and a proven track record of commercialization, it seeks to deliver life-changing therapies.

    • Sorrento Therapeutics
  • Advertisement Feature |

    Biotech company APO-T is developing bispecific T cell engagers (BiTEs) that facilitate the attraction of immune effector cells exclusively to cancer sites by targeting cancer cell antigens known as melanoma-associated antigen A (MAGE-A) proteins.

    • APO-T
  • Advertisement Feature |

    IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.

    • IGY Life Sciences
  • Advertisement Feature |

    Combining the precision of antibody targeting with α-amanitin, a novel payload, Heidelberg Pharma has developed a powerful therapeutic platform, with the potential to treat a broad range of cancers.

    • Heidelberg Pharma
  • Advertisement Feature |

    ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker-related needs.

    • Exosome Diagnostics
  • Advertisement Feature |

    Rakuten Medical, a clinical-stage privately funded biotechnology company, is developing first-in-class targeted cancer therapies based on Illuminox, a new platform with the potential to treat many types of solid tumor, one of the leading causes of death globally.

    • Rakuten Medical
  • Advertisement Feature |

    Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades, and is now working with partners to unlock the therapeutic value of challenging receptors in this class.

    • Beacon Discovery
  • News Feature |

    Partnerships are playing an important role in the pursuit of coronavirus-specific antibodies for diagnostics and therapies for COVID‑19.

    • Biopharma Dealmakers
  • Advertisement Feature |

    GEMoaB’s three proprietary technology platforms have produced a deep pipeline of immunotherapy assets, three of which are currently being investigated in clinical studies, providing the basis for future growth.

    • GEMoaB Monoclonals GmbH
  • Advertisement Feature |

    Life-threatening respiratory diseases remain a key therapeutic area of focus for multinational company Zambon. The company has two phase 3 development programs underway for the treatment of bronchiolitis obliterans syndrome (BOS) and non-cystic fibrosis bronchiectasis (NCFB).

    • Zambon SpA
  • Advertisement Feature |

    Vect-Horus’ versatile drug targeting technology uses receptor-mediated transport to deliver drugs or imaging agents to the brain and cancer tissues.

    • Vect-Horus
  • Advertisement Feature |

    ENPICOM’s ImmunoGenomiX (IGX) Platform offers state-of-the-art immunomics data analysis, management and visualization for academic researchers, drug developers, and related service providers.

    • ENPICOM
  • Advertisement Feature |

    DTx Pharma’s next-generation, fatty acid ligand-conjugated oligonucleotides enable efficient delivery of RNA-based therapeutics to cells and tissues throughout the body. With three disease franchises—ocular, neuromuscular and central nervous system (CNS), DTx is seeking partners to realize the potential of its platform.

    • DTx Pharma
  • Advertisement Feature |

    Karma Oncology combines an agile and adaptable business model with expertise in oncology clinical trials to provide bespoke contract clinical research services for biotechnology companies globally.

    • Karma Oncology
  • Advertisement Feature |

    Privately held Creatv MicroTech has developed LifeTracDx tests to detect cancer at the earliest stages, and for providing diagnoses to guide cancer treatments, thereby saving and improving lives.

    • Creatv MicroTech
  • Advertisement Feature |

    RubrYc Therapeutics has established an antibody discovery engine for the development of epitope-targeted biotherapeutics. Through machine learning, the platform helps reveal natural subdominant and alternative epitopes to target for optimized bio-superior design and as access points to traditionally ‘undruggable’ proteins.

    • RubrYc Therapeutics
  • News Feature |

    Optimization of CAR-T cell technology and application of other immune cell types such as NK cells are tackling the efficacy, cost and logistical challenges of cell therapies for cancer.

    • Nick Taylor
  • Advertisement Feature |

    3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.

    • 3T Biosciences
  • Advertisement Feature |

    Targeting oncology and autoimmune diseases, Byondis takes its pipeline of development programs to clinical proof-of-concept and then seeks partnerships for later-stage clinical development and commercialization.

    • Byondis B.V.
  • Advertisement Feature |

    Japanese company Synplogen uses technology based on over a decade of academic research to design and manufacture long and complex sequences of synthetic DNA. The company is also engaged in novel drug discovery and R&D of gene and cell therapies.

    • Synplogen Co., Ltd.
  • Advertisement Feature |

    Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome from a novel population of cells derived from the amnion. The biological factors secreted by these cells have unique anti-inflammatory and neuroprotective effects. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmic indications.

    • Noveome Biotherapeutics
  • Advertisement Feature |

    Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

    • Sanofi Pasteur
  • Advertisement Feature |

    D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet medical needs. D&D subsidiary Theraly Fibrosis is developing a novel treatment for chronic pancreatitis and other fibrotic indications, TLY012. Neuraly, another D&D subsidiary, recently launched a phase 2 study in Parkinson disease.

    • D&D PharmaTech
  • Advertisement Feature |

    By acting directly on human cell machinery, Atriva Therapeutics’ lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat respiratory diseases such as influenza and COVID-19.

    • Atriva Therapeutics GmbH
  • Advertisement Feature |

    Amicoat’s environmentally friendly antimicrobial coating technology has a broad spectrum of activity with a low risk of provoking antibiotic resistance. The peptide-based technology effectively eliminates biofilms and can be applied to a wide range of medical devices to reduce healthcare-associated infections.

    • Amicoat AS
  • Advertisement Feature |

    MiCAN Technologies has developed Mylc cells, human myeloid lineage cells for use in the study of infectious diseases caused by viruses. The company is also developing a human red blood-like cell product, Mpv. It is hoped that, together, these products will accelerate vaccine and drug development globally.

    • MiCAN Technologies Inc.
  • Advertisement Feature |

    Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning, has provided stable reductions in disease burden and opioid dependence.

    • Aruvant Sciences
  • Advertisement Feature |

    Novadip is designing new treatment options for critical size defects, complex small size defects and surgically inaccessible tissue with its patented 3D tissue regeneration technology platform to transform the lives of patients with unmet medical needs.

    • Novadip Biosciences
  • Advertisement Feature |

    inRegen’s personalized progenitor cell therapy injects autologous kidney cells (REACT) into patients’ damaged kidneys, where cells migrate and restore kidney function. The cell-based treatment is showing signs of promise in ongoing phase 2 trials.

    • inRegen
  • Advertisement Feature |

    Biotech start-up company NovaGo is developing human antibodies that stimulate nerve repair and regeneration following a stroke. The company’s lead candidate anti-Nogo-A antibody (NG004) is ready for phase 1 trials, and it is looking for partners to develop it through the clinic.

    • NovaGo Therapeutics AG
  • Advertisement Feature |

    InVivo Therapeutics is developing a resorbable biomaterial scaffold, the investigational Neuro-Spinal Scaffold,to treat patients with spinal cord injury (SCI). The Neuro-Spinal Scaffold is in clinical trials for acute SCI, and InVivo is also searching for synergistic pipeline expansion opportunities.

    • InVivo Therapeutics